No abstract available.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* ; Splenomegaly*

No abstract available.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

No abstract available.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

No abstract available.
Classification* ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

No abstract available.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

No abstract available.
Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

Background: Detection of BCR/ABL fusion gene has important significance in diagnosing and monitoring response to therapy in chronic myeloid leukemia. Objective: Application of FISH (Fluorescence In Situ Hybrydization) technique for detection of abl/bcr fusion gene in chronic myelogenous leukemia. Subjects and methods: The study included 10 patients of chronic myelogenous leukemia diagnosed by methods of morphology and cell chemistry. Peripheral blood and bone marrow samples of them were analyzed Philadelphia (Ph1) chromosome by cytogenetic technique. Among them, 5 patients were tested by FISH technique on the slide of interphase and remainders were tested by FISH technique on the slide of metaphase cell. Results: Results of analyzing chromosome of 10 patients showed that 8 patients had Ph1 chromosome. 2 patients without Ph1 chromosome were patients who had not high of leukocyte count: 28x109leukocyte/l and 36x109leukocyte/l, respectively. In the FISH on the slide of interphase, all 5 patients had Ph1 chromosome and abl/bcr fusion gene. In the FISH on the slide of metaphase cell, 3 patients had Ph1 chromosome and abl/bcr fusion gene. Conclusion: FISH technique has been applied successfully to detect ABL/BCR gene in patients with chronic myelogenous leukemia.\r\n', u'\r\n', u'
Leukemia ; Myelogenous ; Chronic ; BCR-ABL Positive/ pathology

Background: Chromosome mutation type t(8;21) has quite a high frequency in acute myelogenous leukemia, which accounted for about 15% among adult patients. From 2001, the WHO has a new classification for acute myelogenous leukemia based on genetic mutations. Form had AML1/ETO were arranged into genetic mutation group with better prognosis and ability to fully recover after chemotherapy with a high dose of cytarabin. Objective: Study AML1/ETO fusion gene on the patients diagnosed with Acute Myelogenous Leukemia (AML), as well as the clinical features and some haematologic parameters of the AML1/ETO positive group. Subject and methods: 76 patients with AML were treating in the National Institute of Hematology & Blood Transfusion and the Department of Hematology & Blood Transfusion of Bach Mai Hospital from April 2007 to July 2008. These patients were studied for clinical examination, morphology and RNA were extracted from leukemic cells and PCR for AML1/ETO fusion transcript was performed. Results and conclusions: The incidence of AML1/ETO positive in the AML patients was 24%. The incidence of AML1/ETO positive in AML-M2 was 28%. In the AML1/ETO positive group: median age was 26.94+/-9.22; rate of severe anemia, hemorrhage, fever, infection, hepatomegaly, splenomegaly, lymphadenopathy and gum hypertrophy was 44%, 33%, 28%, 11%, 44%, 28%, 17% and 6%, respectively. Median hemoglobin, WBC, platelet, bone marrow cell count, % blast in peripheral blood and in bone marrow was 84.41+/-28.97 g/l, 29.42+/-31.36 g/l, 42.12+/-33.83 g/l, 215.93+/-134.42 g/l, 56.21+/-26.58% and 65.14+/-16.12%, respectively.
acute myelogenous leukemia ; AML1/ETO fusion gene

No abstract available.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*

No abstract available.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*